Title: The triple reuptake inhibitor DOV 216,303 induces long-lasting enhancement of brain reward activity as measured by intracranial self-stimulation in rats.
Journal: European journal of pharmacology 20121015
Title: Differential BDNF responses of triple versus dual reuptake inhibition in neuronal and astrocytoma cells as well as in rat hippocampus and prefrontal cortex.
Journal: Journal of molecular neuroscience : MN 20120901
Title: Effects of the triple reuptake inhibitor amitifadine on extracellular levels of monoamines in rat brain regions and on locomotor activity.
Journal: Synapse (New York, N.Y.) 20120501
Title: Efficacy and tolerability of the novel triple reuptake inhibitor amitifadine in the treatment of patients with major depressive disorder: a randomized, double-blind, placebo-controlled trial.
Journal: Journal of psychiatric research 20120101
Title: The triple reuptake inhibitor DOV216,303 exhibits limited antidepressant-like properties in the differential reinforcement of low-rate 72-second responding assay, likely due to dopamine reuptake inhibition.
Journal: Journal of psychopharmacology (Oxford, England) 20111001
Title: 1-Heteroaryl-6-(3,4-dichlorophenyl)-3-azabicyclo[4.1.0]heptane: further insights into a class of triple re-uptake inhibitors.
Journal: Bioorganic & medicinal chemistry 20110601
Title: The secrets of a successful clinical trial: compliance, compliance, and compliance.
Journal: Molecular interventions 20110401
Title: Characterization of the electrophysiological properties of triple reuptake inhibitors on monoaminergic neurons.
Journal: The international journal of neuropsychopharmacology 20110301
Title: The potential and limitations of DOV 216,303 as a triple reuptake inhibitor for the treatment of major depression: a microdialysis study in olfactory bulbectomized rats.
Journal: Pharmacology, biochemistry, and behavior 20110101
Title: The novel triple reuptake inhibitor JZAD-IV-22 exhibits an antidepressant pharmacological profile without locomotor stimulant or sensitization properties.
Journal: The Journal of pharmacology and experimental therapeutics 20101201
Title: The putative antidepressant DOV 216,303, a triple reuptake inhibitor, increases monoamine release in the prefrontal cortex of olfactory bulbectomized rats.
Journal: European journal of pharmacology 20100510
Title: The triple monoaminergic reuptake inhibitor DOV 216,303 has antidepressant effects in the rat olfactory bulbectomy model and lacks sexual side effects.
Journal: European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 20081201
Title: The triple uptake inhibitor (1R,5S)-(+)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0] hexane hydrochloride (DOV 21947) reduces body weight and plasma triglycerides in rodent models of diet-induced obesity.
Journal: The Journal of pharmacology and experimental therapeutics 20080301
Title: Triple reuptake inhibitors ('broad spectrum' antidepressants).
Journal: CNS & neurological disorders drug targets 20070401
Title: Stereocontrolled synthesis of trisubstituted cyclopropanes: expedient, atom-economical, asymmetric syntheses of (+)-Bicifadine and DOV21947.
Journal: Organic letters 20060817
Title: Preclinical and clinical pharmacology of DOV 216,303, a 'triple' reuptake inhibitor.
Journal: CNS drug reviews 20060101
Title: DOV 216,303, a 'triple' reuptake inhibitor: safety, tolerability, and pharmacokinetic profile.
Journal: Journal of clinical pharmacology 20041201
Title: 'Broad spectrum' antidepressants: is more better for the treatment of depression?
Journal: Life sciences 20031107
Title: Antidepressant-like actions of DOV 21,947: a 'triple' reuptake inhibitor.
Journal: European journal of pharmacology 20030214
Title: Skolnick P1, et al. Antidepressant-like actions of DOV 21,947: a "triple" reuptake inhibitor. Eur J Pharmacol. 2003 Feb 14;461(2-3):99-104.
Title: Levin ED, et al. Amitifadine, a triple monoamine re-uptake inhibitor, reduces nicotine self-administration in female rats. Eur J Pharmacol. 2015 Jun 20;764:30-37.
